RXDX News Alert Ignyta Inc. (RXDX) 6.70 12/25/2014 11:42:21

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ignyta Inc. (RXDX) 6.70 $RXDX

Ignyta revises terms of entrectinib license agreement with Nerviano
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 8:40AM CST

RXDX: 6.70 (+0.01)

Ignyta Announces Amendment to License Agreement with Nerviano
Business Wire - Mon Dec 15, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that it has entered into an amendment to its license agreement with Nerviano Medical Sciences, S.r.l. relating to its entrectinib (formerly RXDX-101) product candidate. The amendment modifies the milestones that would trigger the initial three milestone payments specified in the license agreement. Pursuant to the amendment, the initial milestone payment of $10 million will be due and payable to Nerviano by December 31, 2014, and the second and third milestone payments will be triggered by revised clinical and/or regulatory events relating to entrectinib or other licensed products. The amounts of such milestone payments have not changed.
RXDX: 6.70 (+0.01)

Ignyta Receives Approval of Nonproprietary Name Entrectinib for Lead Product Candidate, RXDX-101
Business Wire - Tue Dec 09, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) "entrectinib" for the company's lead product candidate, RXDX-101. INNs facilitate the identification of active pharmaceutical ingredients, and each INN is a globally recognized unique name.
RXDX: 6.70 (+0.01)

Ignyta Announces CLIA Certification Achieved by its Diagnostic Laboratory
Business Wire - Tue Dec 02, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its San Diego diagnostic laboratory successfully passed the State of California survey for CLIA (Clinical Laboratory Improvement Amendments) certification. The State of California inspector granted Ignyta permission to begin offering molecular diagnostic services to patients, including those in the company's clinical trials.
RXDX: 6.70 (+0.01)

Ignyta to Present at Upcoming Investor Conferences
Business Wire - Tue Nov 25, 6:00AM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that its management will be making company presentations at the following investor conferences in December 2014:
RXDX: 6.70 (+0.01)

Ignyta Announces RXDX-101 Presentations at the 2014 EORTC-NCI-AACR 'Molecular Targets and Cancer Therapeutics' Conference
Business Wire - Tue Nov 18, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced the acceptance of two abstracts for poster presentations relating to RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. The poster presentations will be held on November 20-21, 2014 in Barcelona, Spain.
RXDX: 6.70 (+0.01)

Ignyta's (RXDX) CEO Jonathan Lim on Q3 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 6:06PM CST

RXDX: 6.70 (+0.01)

Ignyta posts 3Q loss
Automated Insights - Fri Nov 07, 3:07PM CST
SAN DIEGO (AP) _ Ignyta Inc. (RXDX) on Friday reported a loss of $10.7 million, or 55 cents per share, in its third quarter.
RXDX: 6.70 (+0.01)

Ignyta misses by $0.12
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:03PM CST

RXDX: 6.70 (+0.01)

Ignyta Announces Third Quarter 2014 Company Highlights and Financial Results
Business Wire - Fri Nov 07, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the third quarter ended September 30, 2014.
RXDX: 6.70 (+0.01)

Ignyta to Chair the Institute of Medicine's National Cancer Policy Forum Workshop on Molecularly Targeted Cancer Therapies
Business Wire - Mon Nov 03, 3:00PM CST
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chief Medical Officer, Adrian Senderowicz, M.D., has been selected to serve as Workshop Planning Committee Chair for the workshop entitled Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer. The event will be hosted by the Institute of Medicine's National Cancer Policy Forum on November 10 and 11, 2014 at the Keck Center of the National Academies in Washington, D.C.
RXDX: 6.70 (+0.01)

Ignyta to Report 2014 Third Quarter Company Highlights and Financial Results and Host Conference Call on November 7, 2014
Business Wire - Fri Oct 31, 4:29PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an precision oncology biotechnology company, announced today that it will release its third quarter 2014 financial results after the market closes on Friday, November 7, 2014. Ignyta management will host a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to provide company highlights, review the financial results and answer questions.
RXDX: 6.70 (+0.01)

Ignyta to Host Investor Meeting with Oncology Key Opinion Leaders on October 14, 2014
Business Wire - Thu Oct 02, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it will host a Key Opinion Leader Breakfast on Tuesday, October 14, 2014 from 8:00-9:30 a.m. Eastern time in New York City.
RXDX: 6.70 (+0.01)

Ignyta Secures $31 Million Term Loan Facility from Silicon Valley Bank
Business Wire - Wed Oct 01, 3:30PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it has secured a $31 million term loan facility from Silicon Valley Bank. Under the loan facility, the company received initial funding of $21 million, approximately $11 million of which was used to repay the company's existing loan with Silicon Valley Bank, and has a conditional option to receive an additional $10 million.
RXDX: 6.70 (+0.01)

Ignyta Announces Interim Data from RXDX-101 Phase I Clinical Trial at 2014 ESMO Congress
Business Wire - Sun Sep 28, 7:00AM CDT
--To date, one complete response in a patient with a ROS1 alteration, partial responses in five patients with each of TrkA, ROS1 and ALK alterations, and prolonged stable disease in two patients
RXDX: 6.70 (+0.01)

Ignyta to Present at Livingston Securities Life Science Stakeholders Summit
Business Wire - Thu Sep 25, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Jacob Chacko, M.D., Chief Financial Officer, will make a presentation at the Livingston Securities Life Science Stakeholders Summit on October 1, 2014 at 1:30 p.m. Eastern time (10:30 a.m. Pacific time) in Philadelphia, PA.
RXDX: 6.70 (+0.01)

Nasdaq stocks posting largest percentage decreases
AP - Fri Sep 19, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
EVOK: 5.50 (-0.26), ALCS: 0.30 (+0.01), UNXL: 5.77 (+0.07), RXDX: 6.70 (+0.01), FULL: 4.76 (-0.01), RLYP: 30.35 (-0.22), BBSI: 28.34 (+0.38), NVSL: 8.58 (+0.09), RPRX: 8.88 (+0.24), HGSH: 4.60 (-0.06), LPCN: 5.15 (+0.01), NYNY: 7.89 (+0.32)

Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders
Business Wire - Wed Sep 17, 6:00AM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that its Chairman and CEO, Jonathan Lim, M.D., has been invited to participate in upcoming panel discussions relating to innovation in Rx/Dx strategies and novel science developments in precision medicine.
BIIB: 340.89 (+5.13), RXDX: 6.70 (+0.01)

Ignyta Announces RXDX-101 Phase I Data Presentation at the 2014 ESMO Congress
Business Wire - Mon Sep 15, 3:00PM CDT
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for presentation in a poster discussion session at the 2014 Congress of the European Society for Medical Oncology (ESMO), which is being held from September 26-30, 2014 in Madrid, Spain.
RXDX: 6.70 (+0.01)

Ignyta (RXDX) Jumps: Stock Adds 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 7:51AM CDT
Ignyta, Inc. (RXDX) was a big mover last session, as its shares rose nearly 6% on the day.
LCI: 42.29 (+1.79), ENDP: 72.10 (+0.34), RXDX: 6.70 (+0.01), HPTX: 21.91 (-0.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dallas College Recognition Signals Workforce Value

Updated Category News Views 49

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 113

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Four Data Quality Champions Put Trust on the Board

Updated Category News Views 65

A single rotten customer record can gum up an entire operation faster than most executives care to admit. Bad data does not merely make a dashboard look silly; it can foul forecasts, duplicate work, misdirect automation, and leave an AI project confidently spouting nonsense. That is why Infotech's 2026 Data Quality Emotional Footprint report deserves a look, even if...

Continue Reading
Re-Decking or Rebuilding Starts Below the Deck Boards

Updated Category News Views 47

A weathered deck can fool the eye in both directions: ugly boards may sit atop solid framing, while a tidy surface can hide trouble where nobody bothers to look. That is the useful, sober point in Dawn Walsh's guidance for Knoxville homeowners. The decision is not really about whether the top boards look tired. It is about whether the bones underneath still deserve...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 100

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 37

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 71

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading

Top 5 Most Recently Viewed Articles

DatChat Receives Mexican Patent for Enhanced Privacy Solutions

Updated Category News Views 157

DatChat's Latest Patent Achievement New Brunswick, NJ - DatChat, Inc. (NASDAQ: DATS), a leading company in secure messaging and social media, has exciting news to share. Recently, the Mexican Patent office issued a Notice of Allowance for DatChat's patent application titled "Systems and Methods of Transforming Electronic Content." This development follows the company...

Continue Reading
Flora Growth Partners with Canopy to Enhance Cannabis Access

Updated Category News Views 111

Flora Growth Enters the Australian Medical Cannabis Market Flora Growth Corp (NASDAQ: FLGC) has recently taken a significant step into the Australian medical cannabis arena through its strategic partnership with Canopy Growth Corp (NASDAQ: CGC). A distribution agreement has been signed, allowing Flora's subsidiary, Australian Vaporizers, to handle the distribution of...

Continue Reading
Digital Brands Group Sets Public Offering of 11.36 Million Units

Updated Category News Views 167

Digital Brands Group Projects Strong Growth with New Offering Digital Brands Group, Inc. (OTC PINK: DBGI), a unique entity known for curating luxury lifestyle brands, has recently made headlines with their announcement regarding a public offering. This initiative, which involves an impressive volume of 11.36 million units, is set to make waves in the market. Details of...

Continue Reading
Unraveling Solana's Remarkable Rise From $11 to $166

Updated Category News Views 154

Unraveling Solana's Remarkable Rise From $11 to $166 Solana (SOL), a cryptocurrency that emerged in March 2020, has astonished investors with its dramatic increase in value. It has risen more than 15 times its initial value, predominantly bolstered by a vibrant ecosystem that has flourished around various meme coins. Jim Cramer’s Warning In 2022, Jim Cramer, a prominent...

Continue Reading
LO3 Capital Revolutionizes Travel Services with CCRA Deal

Updated Category News Views 189

LO3 Capital Makes Strategic Investment in CCRA International LO3 Capital, a dynamic private investment firm, is making waves with its recent senior debt investment in CCRA International, Inc. This relationship is pivotal for CCRA, a technology-driven travel services platform, as it progresses towards acquiring ABC Global Services. This acquisition is set to form one of...

Continue Reading